Clinical trials: Metastatic Colorectal Neoplasms
Metastatic Carcinoma in the Liver, MLH1 Gene Mutation
Durvalumab and Tremelimumab in Treating Patients With Microsatellite Stable Metastatic Colorectal Cancer to the Liver
This pilot clinical trial studies the side effects and how well durvalumab and tremelimumab work in treating patients with microsatellite stable colorectal cancer that has spread to the liver.
- Conditions
- Metastatic Carcinoma in the Liver, MLH1 Gene Mutation, MSH6 Gene Mutation, PMS2 Gene Mutation
- Trial name
- NCT03005002
- Testing
- Durvalumab, Laboratory Biomarker Analysis, Tremelimumab
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- City of Hope Medical Center
Colorectal Cancer Metastatic
Study of Durvalumab and Tremelimumab After Radiation for Microsatellite Stable Metastatic Colorectal Cancer Progressing on Chemotherapy
This study is being done to look at the safety and response to the combination of two investigational drugs, tremelimumab and durvalumab, when given after radiation therapy for patients with microsatellite stable (MSS) metastatic…
- Trial name
- NCT03007407
- Testing
- durvalumab, Tremelimumab
- Where
- 18 sites in United States
- Volunteers
- 33 people
- Sponsor
- NSABP Foundation Inc
Breast Cancer, Prostate Cancer
Collection of Blood Specimens for Circulating Tumor Cell Analysis
Objective: To test the sensitivity of a proprietary novel filtration device designed to capture and concentrate circulating tumor cells (CTCs).
- Conditions
- Breast Cancer, Prostate Cancer, Colorectal Cancer
- Trial name
- NCT01943500
- Where
- United States
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Viatar LLC
Colorectal Cancer
Aspirin for Prevention of Postsurgical Recurrence and Metastasis in Asian Colorectal Cancer Patients: a Multi-center Randomized Trial
Background: Evidence of high quality has suggested that acetylsalicylic acid (ASA)/aspirin effectively reduces colorectal adenoma incidence and recurrence rate, and several randomized controlled trials (RCTs) strongly indicate…
- Trial name
- APREMEC (NCT02607072)
- Testing
- Acetylsalicylic acid (ASA)/aspirin 200 mg daily, Acetylsalicylic acid (ASA)/aspirin 100 mg daily
- Where
- China
- Volunteers
- 3,000 people
- Sponsor
- The Fourth Affiliated Hospital of Anhui Medical University
Advanced or Metastatic CRC
Clinical Study of Utidelone Injection in Patients With Advanced or Metastatic Colorectal Cancer
To assess the effectiveness and safety of utidelone injection in patients with advanced or metastatic colorectal cancer (CRC) as a phase II trial
- Trial name
- NCT03906565
- Testing
- utidelone injection
- Where
- 5 sites in China
- Volunteers
- 30 people
- Sponsor
- Beijing Biostar Pharmaceuticals Co., Ltd.
Rectal Neoplasms, Neoplastic Cells, Circulating
Change of Circulating Tumor Cells During Laparoscopic or Transanal Endoscopic Surgery for Rectal Cancer.
The primary purpose of this study is to compare the changes of circulating tumor cells (CTCs) at different time points in rectal cancer patients undergoing laparoscopic or transanal endoscopic radical resection.
- Conditions
- Rectal Neoplasms, Neoplastic Cells, Circulating, Laparoscopic Surgery, Transanal Endoscopic Surgery
- Trial name
- NCT05109130
- Testing
- Surgical approach
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Sun Yat-sen University
Colorectal Cancer
Curative Proton Beam Therapy for Patients With Liver Metastasis of Colorectal Cancer
Proton alone therapy is performed -> 5 times a week, 7200 cGy / 15 fractions for 3 weeks total
- Trial name
- NCT03577665
- Testing
- curative proton therapy
- Where
- South Korea
- Volunteers
- 30 people
- Sponsor
- National Cancer Center, Korea
Colorectal Cancer
Phase II Study to Evaluate G17DT in Combination With Irinotecan in Patients With Colorectal Carcinoma
This study was designed to evaluate the ability for G17DT to slow or arrest tumor growth in patients with refractory colon cancer who had been previously treated with an Irinotecan-based chemotherapy.
- Trial name
- CC6 (NCT02118064)
- Testing
- G17DT-Irinotecan
- Volunteers
- 161 people
- Sponsor
- Cancer Advances Inc.
Colorectal Cancer, Liver Metastases
Adjuvant Xeloda Plus Eloxatin +/- Avastin After Radical Resection of Liver Metastasis of Colorectal Cancer
The primary aim of this study is to investigate whether the addition of the new anti-cancer drug bevacizumab (Avastin) to the combination of the chemotherapeutic agents capecitabine (Xeloda) and oxaliplatin (Eloxatin) reduces…
- Trial name
- NCT00394992
- Testing
- oxaliplatin+capecitabine, Oxaliplatin+capecitabine+bevacizumab
- Where
- Netherlands
- Volunteers
- 79 people
- Sponsor
- Dutch Colorectal Cancer Group
Recurrent Colon Cancer, Recurrent Rectal Cancer
MEK Inhibitor MEK162 in Combination With Leucovorin Calcium, Fluorouracil, and Oxaliplatin in Treating Patients With Advanced Metastatic Colorectal Cancer
This phase I trial studies the side effects and best dose of MEK inhibitor MEK162 when given together with leucovorin calcium, fluorouracil, and oxaliplatin in treating patients with advanced metastatic colorectal cancer.
- Conditions
- Recurrent Colon Cancer, Recurrent Rectal Cancer, Stage IVA Colon Cancer, Stage IVA Rectal Cancer
- Trial name
- NCT02041481
- Testing
- MEK inhibitor MEK162, leucovorin calcium, fluorouracil
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- City of Hope Medical Center
Metastatic Colorectal Cancer
Technical Optimization of Detection of KRAS, BRAF and NRAS Mutations on Tumor DNA Circulating in Metastatic Colorectal Cancer
The objective of this study is to optimize the search by next-generation sequencing (NGS) mutations in the KRAS, BRAF and NRAS on circulating tumor DNA and compare the genetic profiles obtained with those from tumors embedded in…
- Trial name
- CircuLOR-1 (NCT02827565)
- Testing
- KRAS, NRAS et BRAF mutation analysis from circulating plasma DNA
- Where
- France
- Volunteers
- 30 people
- Sponsor
- Institut de Cancérologie de Lorraine
Colorectal Cancer, Colorectal Carcinoma
A Phase 1 Study Investigating the Combination of RAD001, Cetuximab and Irinotecan as Second-line Therapy After FOLFOX (or XELOX) Plus Bevacizumab in Patients With Metastatic Colorectal Cancer
This study will assess the safety of RAD001 when given together with cetuximab and irinotecan
- Conditions
- Colorectal Cancer, Colorectal Carcinoma, Colorectal Tumors, Neoplasms, Colorectal
- Trial name
- NCT00478634
- Testing
- RAD001, Cetuximab, Irinotecan
- Where
- 16 sites in United States
- Volunteers
- 19 people
- Sponsor
- Novartis Pharmaceuticals
Left-sided Colorectal Cancer
Study of Petosemtamab Plus Chemotherapy Versus Cetuximab Plus Chemotherapy in RAS and BRAF Wild-type, Unresectable or Metastatic, Left-sided Colorectal Cancer (LiGeR-CRC1)
The purpose of this trial is to evaluate how well petosemtamab in combination with chemotherapy works against colorectal cancer located on the left side of the colon that cannot be safely removed by surgery or has spread to other…
- Trial name
- NCT07702032
- Testing
- Petosemtamab, Cetuximab, FOLFIRI
- Where
- 12 sites in United States, Australia and 1 more
- Volunteers
- 960 people
- Sponsor
- Genmab
Breast Cancer, Non-small Cell Lung Cancer
Integrated Molecular Profiling in Advanced Cancers Trial
Substantial progress has been made in the treatment of cancer through the use of targeted therapies, but what works for one patient might not work for another patient.
- Conditions
- Breast Cancer, Non-small Cell Lung Cancer, Colorectal Cancer, Genitourinary Cancer
- Trial name
- IMPACT (NCT01505400)
- Where
- Canada
- Volunteers
- 3,026 people
- Sponsor
- University Health Network, Toronto
Secondary Malignant Neoplasm of Liver
Hepatic Vein-sparing Hepatectomy for Colorectal Liver Metastases at the Caval Confluence
Major hepatectomies are generally selected for tumors involving the hepatic vein (HV) at the caval confluence (CC). As alternative, HV reconstruction has been proposed.
- Trial name
- NCT02391207
- Testing
- Hepatic vein-sparing hepatectomy
- Where
- Italy
- Volunteers
- 50 people
- Sponsor
- University of Milan
Metastatic Malignant Neoplasm
A Study of NPX267 for Subjects With Solid Tumors Known to Express HHLA2/B7-H7
NPX267 is an antibody drug targeting the inhibitory receptor for B7-H7 (HHLA2) which may control evasion of the immune response in tumors.
- Trial name
- NCT05958199
- Testing
- NPX267
- Where
- 7 sites in United States
- Volunteers
- 131 people
- Sponsor
- NextPoint Therapeutics, Inc.
Metastatic Colorectal Cancer
A Retrospective Review of Liver Resection Rate in Metastatic Colorectal Cancer Patients Following Downsizing Treatment With Chemotherapy Plus Cetuximab in Normal UK National Health Service Clinical Practice
This study is a multi-centre retrospective observational research study which will be conducted in UK centres with specialised liver surgical services.
- Trial name
- RESECT (NCT01460745)
- Where
- 5 sites in United Kingdom
- Volunteers
- 60 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Colorectal Cancer
Study of Bevacizumab Alone or Combined With Capecitabine and Oxaliplatin as Support Therapy in Metastatic Colorectal Cancer Patients
The purpose of this study is to compare the free time to disease progression of combination therapy with capecitabine, oxaliplatin and bevacizumab until disease progression versus capecitabine, oxaliplatin and bevacizumab for 6…
- Trial name
- NCT00335595
- Testing
- XELOXA, XELOXA-A
- Where
- Spain
- Volunteers
- 480 people
- Sponsor
- Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)
Metastatic Colorectal Cancer (CRC)
A Study of DES-1357 in People With Deficient Mismatch Repair (dMMR)/Microsatellite Instability-High (MSI-H) Metastatic Colorectal Cancer (mCRC)
This study is conducted sequentially in 3 parts. The primary objective for Part 1 is to determine the maximum tolerated dose of DES-1357 in participants with confirmed dMMR/MSI-H colorectal cancer (CRC).
- Trial name
- NCT07807800
- Testing
- DES-1357
- Volunteers
- 88 people
- Sponsor
- D. E. Shaw Research, LLC
Solid Tumors, Advanced Malignancies
Azacitidine Combined With Pembrolizumab and Epacadostat in Subjects With Advanced Solid Tumors (ECHO-206)
This is an open-label, Phase 1/2 study in subjects with advanced or metastatic solid tumors. The study has three separate treatment groups where separate epigenetic agents are evaluated with an immunotherapy combination.
- Conditions
- Solid Tumors, Advanced Malignancies, Metastatic Cancer
- Trial name
- NCT02959437
- Testing
- Azacitidine, Pembrolizumab, Epacadostat
- Where
- 12 sites in United States, Spain and 1 more
- Volunteers
- 70 people
- Sponsor
- Incyte Corporation
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.